Lars Fruergaard Jørgensen

Lars Fruergaard Jørgensen is a Danish businessman who currently serves as the president and chief executive officer (CEO) of Novo Nordisk, a global healthcare company specializing in diabetes care. Jørgensen has a long history with Novo Nordisk, having joined the company in 1991 as an economist in Health Care, Economy & Planning.

Over the years, Jørgensen has held various positions within Novo Nordisk, including overseas postings in the Netherlands, the United States, and Japan, where he gained valuable international experience. In 2004, he was appointed senior vice president for IT & Corporate Development, overseeing the company's information technology functions and corporate development initiatives.

In January 2013, Jørgensen assumed the role of executive vice president and chief information officer, expanding his responsibilities to include IT, Quality & Corporate Development. He played a crucial role in driving technological advancements and ensuring quality standards across the organization. Later that year, he also took on the responsibilities for Corporate People & Organisation and Business Assurance, serving as chief of staff.

Recognizing his significant contributions and leadership capabilities, Jørgensen was appointed as the president and CEO of Novo Nordisk in January 2017. In this role, he has been instrumental in guiding the company's strategic direction and overseeing its operations worldwide. Jørgensen's deep understanding of the healthcare industry and his commitment to innovation have helped Novo Nordisk maintain its position as a global leader in diabetes care.

Outside of Novo Nordisk, Jørgensen holds the position of first vice president of the European Federation of Pharmaceutical Industries and Associations (EFPIA). This role allows him to contribute to shaping the pharmaceutical industry and advocate for policies that promote patient access to innovative treatments.

Jørgensen holds a Master of Science (MSc) degree in Finance and Business Administration from the Aarhus School of Business, Aarhus University in Denmark. As a Danish national, he was born in November 1966. With his extensive experience and leadership in the pharmaceutical sector, Lars Fruergaard Jørgensen continues to play a significant role in advancing healthcare and improving the lives of people affected by diabetes globally.

Lars Fruergaard Jørgensen is a Danish business executive who has made significant contributions to the healthcare industry, particularly in the field of diabetes care. He is currently serving as the President and CEO of Novo Nordisk, a global pharmaceutical company headquartered in Denmark.

Jørgensen's journey with Novo Nordisk began in 1991 when he joined the company as an economist in the Health Care, Economy & Planning department. Throughout his career, he has held various leadership positions within the organization, both in Denmark and internationally.

In 2004, Jørgensen was appointed as the Senior Vice President for IT & Corporate Development, where he played a crucial role in leveraging technology and driving corporate growth initiatives. His ability to navigate the complex landscape of information technology and corporate strategy led to his promotion to the Executive Vice President of IT, Quality & Corporate Development in January 2013. In this role, he was responsible for ensuring the highest standards of quality across the organization while driving the company's IT capabilities to support its business operations.

Jørgensen's leadership skills and business acumen continued to shine, and in December 2014, he assumed the position of Executive Vice President for Corporate Development. During this time, he oversaw strategic initiatives and played a pivotal role in shaping Novo Nordisk's future direction.

Recognizing his exceptional contributions and deep understanding of the company, Lars Fruergaard Jørgensen was appointed as President and CEO of Novo Nordisk in January 2017. In this role, he has spearheaded the company's mission to improve the lives of people living with diabetes through innovative research, development, and delivery of diabetes care solutions. Under his leadership, Novo Nordisk has continued to advance its position as a global leader in diabetes care, focusing on developing cutting-edge treatments and therapies.

Beyond his role at Novo Nordisk, Jørgensen is actively involved in the pharmaceutical industry. He serves as the first vice-president of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he contributes to shaping industry policies and promoting access to healthcare innovations.

Jørgensen holds a Master of Science (MSc) degree in Finance and Business Administration from the Aarhus School of Business, Aarhus University in Denmark. His passion for improving patient outcomes and his visionary leadership have solidified his reputation as a respected figure in the healthcare sector. With his extensive experience and dedication to making a difference, Lars Fruergaard Jørgensen continues to drive Novo Nordisk's mission to change diabetes for the better.

Under Jørgensen's leadership, Novo Nordisk aims to be at the forefront of diabetes care, continuously pushing the boundaries of medical advancements. The company's vision is centred around three key pillars: innovation, patient-centricity, and sustainability.

Innovation is a core component of Jørgensen's vision. He recognizes the importance of constantly exploring new scientific frontiers and developing breakthrough treatments and therapies. By investing in cutting-edge research and development, Novo Nordisk strives to offer innovative solutions that address the evolving needs of patients. Jørgensen encourages a culture of creativity and collaboration within the company, fostering an environment that nurtures groundbreaking ideas and transformative discoveries.

Central to Jørgensen's vision is a deep commitment to patient-centricity. He believes that healthcare should be centred around the needs and aspirations of the patients it serves. Novo Nordisk is dedicated to understanding the challenges faced by individuals with diabetes and other chronic diseases and developing solutions that truly make a positive impact on their lives. By placing patients at the heart of everything they do, the company aims to create meaningful and sustainable improvements in healthcare outcomes.

Sustainability is another crucial aspect of Jørgensen's vision for Novo Nordisk. He recognizes the importance of responsible business practices that not only benefit patients but also contribute to a healthier society and a more sustainable planet. Novo Nordisk aims to integrate sustainability into its operations, supply chain, and product life cycles, minimizing environmental impact and actively engaging in initiatives that address global healthcare challenges.

Jørgensen's vision extends beyond Novo Nordisk's immediate impact. He actively advocates for collaboration and partnerships with stakeholders across the healthcare ecosystem, including governments, healthcare providers, patient organizations, and industry peers. By working together, Jørgensen believes that it is possible to drive systemic change and shape a future where accessible and high-quality healthcare is available to all.

Through his visionary leadership, Lars Fruergaard Jørgensen inspires Novo Nordisk to push the boundaries of innovation, prioritize patient needs, and contribute to a sustainable healthcare future. His unwavering commitment to improving the lives of patients and his belief in the power of collaboration position Novo Nordisk as a leading force in the global healthcare landscape.